Carcinoma of Unknown Primary with EML4‐ALK Fusion Response to ALK Inhibitors

With the advent of next‐generation sequencing (NGS) and precision medicine, investigators have determined that tumors from different tissue sources that have the same types of genetic mutations will have a positive response to the same targeted therapy. This finding has prompted us to seek potential...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Oncologist
Päätekijät: Zhao, Peng, Peng, Ling, Wu, Wei, Zheng, Yi, Jiang, Weiqin, Zhang, Hangyu, Tong, Zhou, Liu, Lulu, Ma, Ruobing, Wang, Liping, Yao, Ming, Wang, Kai, Fang, Weijia, Wu, Liming
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: John Wiley & Sons, Inc. 2019
Aiheet:
Precision Medicine Clinic: Molecular Tumor Board
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6459257/
https://ncbi.nlm.nih.gov/pubmed/30679319
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0439
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia